This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.
MOTS-C
Mitochondria-derived peptide with preclinical metabolic/exercise-related findings; limited established human efficacy evidence.
Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.
In mice, MOTS-c treatment improved treadmill running performance under diet-induced metabolic stress & showed metabolic regulatory effects.
Reviews propose metabolic & stress-response roles primarily based on preclinical evidence; no effective method of applying MOTS-c in the clinic has been established as of 2024-2025.
Reviews note that clinical trials to test therapeutic MOTS-c potential are limited/ongoing; overall human efficacy evidence remains early. Blood MOTS-c levels are reported lower in type 2 diabetes & obesity, but therapeutic dosing in humans has not been validated.
Stacks containing MOTS-C
Public community stacks that include this ingredient.
Mitochondria-oriented peptide grouping. SS-31 has clinical trials in specific mitochondrial diseases; MOTS-C is mostly preclinical.